CSPC Innovation Pharmaceutical (300765) Q4 2024 earnings summary

Executive summary

• Net profit attributable to shareholders was RMB 53.73 million, down 87.63% year-over-year, mainly due to a sharp decline in caffeine prices and increased R&D investment.

• Functional food and raw material business maintained profitability with net profit of RMB 425 million despite market headwinds.

• Strategic transformation into biopharmaceuticals advanced, with key product launches and pipeline progress.

Financial highlights

• Revenue for 2024 was RMB 1.98 billion, down 21.98% year-over-year.

• Net profit attributable to shareholders was RMB 53.73 million, down 87.63% year-over-year.

• Basic and diluted EPS were RMB 0.0384, down 87.65% year-over-year.

• Gross margin for functional food and raw materials was 39.73%; for biopharmaceuticals, 95.16%.

• R&D expenses increased 25.44% to RMB 842 million, accounting for 42.52% of revenue.

• Operating cash flow was negative RMB 1.24 billion, mainly due to historical R&D payments and large investments.

Outlook and guidance

• Focus on accelerating innovative drug R&D and commercialization, with over 20 projects in the pipeline.

• Plans to consolidate leadership in functional raw materials and expand into new product areas.

• Continued commitment to sustainable development, safety, and environmental protection.